Twist Bioscience Corp: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 2, 2024 and accepted by EDGAR at Aug 2, 2024, 16:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $81.5m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2023-10-01 to 2024-06-30 | $228.3m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $46.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2023-10-01 to 2024-06-30 | $133.1m | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $22.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-10-01 to 2024-06-30 | $69.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $56.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-10-01 to 2024-06-30 | $165.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$88.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-10-01 to 2024-06-30 | −$184.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $0 | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2023-10-01 to 2024-06-30 | $0 | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $191.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-10-01 to 2024-06-30 | $656.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$85.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-10-01 to 2024-06-30 | −$174.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$1.47 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-10-01 to 2024-06-30 | −$3.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$1.47 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-10-01 to 2024-06-30 | −$3.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 58,145,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-10-01 to 2024-06-30 | 57,806,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-10-01 to 2024-06-30 | −$48.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-10-01 to 2024-06-30 | $3.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $239.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $361.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $638.1m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $73.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $147.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | $491.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-034434. Last ingested by Listed: Oct 27, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.